Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Study ID
- NCT07476105
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma Grade 3B
Eligibility Criteria
- Sex
- ALL
- Age
- 70 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Geriatric-guided supportive care — OTHERStructured geriatric consultation, along with a nutritional and physiotherapy evaluation, before treatment initiation and with subsequent follow-up assessments aimed at optimizing comorbidity management, nutritional and functional status, along with treatment tolerance.
- Conventional supportive care — OTHERSupportive care will be delivered according to local clinical practice
Study Details
The aim of this multicenter, non-randomized, cluster controlled trial study is to evaluate the impact of a geriatric-guided approach with a pro-active rehabilitative/nutritional plan for elderly unfit/frail DLBCL patients eligible for receiving chemoimmunotherapy according to the sGA, versus a conventional approach with onco-hematological treatment alone. A key innovation element of this project is to use a geriatric-guided approach to improve the global management of all frailty aspects (nutritional, functional, cognitive, social), chasing a better tolerance and completion rate of treatment, tailoring safety and efficacy of therapies in unfit/frail DLBCL patients. This study may lead to a personalized approach for elderly DLBCL patients, taking into account a multidisciplinary and fully-integrated program, with the primary aim of improving the quality of life of patients and their families.
Key Dates
- First listed
- Mar 17, 2026
- Start date
- May 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Nov 30, 2028
- Completion
- May 31, 2029
Study Design
- Enrollment
- 170 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Geriatric-guided supportive carePatients will be treated for lymphoma according to standard clinical practice. Patients will receive a geriatric-guided supportive care with structured geriatric consultation, along with a nutritional and physiotherapy evaluation, before treatment initiation and with subsequent follow-up assessments aimed at optimizing comorbidity management, nutritional and functional status, along with treatment tolerance.
- Active Comparator: Conventional supportive carePatients will be treated for lymphoma according to standard clinical practice. Patients will receive supportive care according to standard clinical practice without systematic geriatric input.
Primary Outcome Measure
To evaluate whether a geriatric-guided approach improves health-related quality of life (HRQL) in elderly patients with DLBCL eligible for first-line chemoimmunotherapy, compared to a conventional approach. [ Time Frame: From the beginning of the study up to 6 months after last enrolled patient (up 30 months from study beginning) ]
Central Contacts
- Uffici Studi FIL+390131033153
- Uffici Studi FIL+390599769913
Related Studies
- Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruiting · Medical College of Wisconsin · Milwaukee, Wisconsin
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesPHASE1/PHASE2 · Recruiting · Medical College of Wisconsin · Milwaukee, Wisconsin